top of page



Akthelia featured in Icelandic business newspaper Viðskiptablaðið
Viðskiptablaðið, a leading Icelandic business newspaper, has published an extensive article on Akthelia’s current position and future plans. The article, based on an interview with Akthelia’s CEO, Egill Másson, covers the company’s plans to start human studies with its drug candidate AKT-011. Egill states that moving from preclinical research into clinical trials is always a big step for drug development companies and will create new opportunities for financing and collaborat
Akthelia News Desk
4 days ago


Approaching the Clinical Inflection Point
Akthelia Pharmaceuticals held a presentation this week following its Annual General Meeting at Hilton Reykjavík Nordica, under the title Approaching the Clinical Inflection Point. The meeting covered the company’s current status, its next development steps, and the path toward clinical trials. The briefing brought together shareholders, advisors, and members of Akthelia’s scientific and medical network. A special guest at the meeting was Prof. Dr. Markus Gerhard, a physician
Akthelia News Desk
May 19


Akthelia Files New Patent Following IN-ARMOR Licensing Agreement
Akthelia Pharmaceuticals has filed a new UK patent application, marking an important milestone in the expansion of the company’s innovation pipeline. The patent filing follows the signing of a licensing agreement in December with partners in the Horizon Europe IN-ARMOR project. The collaboration focuses on the discovery and optimisation of novel immune-modulating small molecules, together with Enamine, a Ukrainian contract research organization (CRO) specializing in medici
Akthelia News Desk
Feb 3


Brynjolfur Thor Gylfason joins Akthelia as Financial controller
Icelandic biotech R&D company Akthelia Pharmaceuticals has appointed Brynjólfur Þór Gylfason as Financial Controller. Gylfason brings more than twenty years of financial leadership experience across the biotechnology and healthcare sectors, investment management, and advisory services. He joins Akthelia from GS Holdings Group. He has also held roles at Danforth Advisors, WuXi NextCODE, Virðing hf., and Deloitte. Gylfason holds a Cand. Oecon. degree in Auditing from the Univer
Akthelia News Desk
Nov 1, 2025


Stefán Jónsson joins Akthelia as Director of CMC
Icelandic biotech R&D company Akthelia Pharmaceuticals has appointed Stefán Jónsson, PhD, as Head of Chemistry, Manufacturing, and Control (CMC) and Intellectual Property. In this role, Dr. Jónsson will lead strategy and execution across development, analytical, and manufacturing processes, pharmaceutical substances and formulations, as well as the company’s intellectual property strategy. Dr. Jónsson brings two decades of experience in analytical methodologies, proteomics, m
Akthelia News Desk
Aug 3, 2025
bottom of page